68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors
Status:
Completed
Trial end date:
2017-12-05
Target enrollment:
Participant gender:
Summary
To evaluate the concordance and discordance between results of 68Ga-DOTATATE PET-CT scan and
OctreoScan ® which is considered standard of care diagnostic test for neuroendocrine cancers
and other imaging modalities like CT scan/MRI as gold standard.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Radio Isotope Therapy of America
Collaborators:
Excel Diagnostics and Nuclear Oncology Center RadioMedix Radiomedix, Inc.